arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Solid Biosciences Inc.

SLDB
$8.38 ▼ -0.32 (-3.73%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
10 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Solid Biosciences Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $733.3M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -99.6%
FCF / Share $-1.80
Trailing P/E
Price / Book 3.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.09M
↓ -40.6%
Net Income Profit after all expenses
$-174.32M
↓ -39.8%
FCF / Share Free cash flow per share
$-1.80
↑ +27.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters